
DJIBOUTI

CERVICAL CANCER PROFILE


Morbidity and Mortality

TOTAL DEATHS, FEMALE (2019): **3 200**



Primary Prevention

HPV vaccination programme coverage among girls (2020)



HPV vaccination is not included in the national vaccination schedule

Secondary Prevention

National screening programme	
for cervical cancer exists (2021):	No
Primary screening test used (2021):	-
Target age range of programme (2021):	-
Programme/guidelines exist to strengthen early detection	
of first symptoms at primary health care level (2021):	No
Clearly defined referral system exists from primary care	
to secondary and tertiary care (2021):	No

Treatment and Supportive Care

National guidelines on cervical cancer management	
exist (2021):	No

Cancer diagnosis and treatment services generally available (2021):

Cancer centre or cancer department at tertiary level:	No
Pathology services (laboratories):	Yes
Cancer surgery:	Yes
Chemotherapy:	No
Radiotherapy:	No


HPV vaccination programme (2020):

HPV included in national vaccination programme:	No
Scale of vaccination programme:	-
Year of introduction:	-
Primary target cohort:	-

Related risk factors:

Tobacco use prevalence, women aged 15+ years (2020):	ND
Condom use at last high-risk sex (-):	ND
HIV incidence per 1000, women aged 15+ years (2020):	0.13

Screening for cervical cancer (2019)



Fewer than 1 in 10 women have been screened for cervical cancer in the last 5 years

Number of radiotherapy units per 10 000 cancer patients (-):	ND
Number of brachytherapy units per 10 000 cancer patients (-):	ND

Number of medical staff (per 10 000 cancer patients):

ND
0
252
ND
0

Palliative care for patients with NCDs in the public health system generally available (2021):

In primary health care facilities:	No	(
In community or home-based care:	No	(

Reported annual opioid consumption excluding methadone - in oral morphine equivalence per capita (2017): **Omg**

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15

70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age

90% of women identified with cervical disease receive treatment

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls) † Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions